2. Signaling Pathways
  3. Apoptosis
  4. DAPK
  5. DAPK Inhibitor

DAPK Inhibitor

DAPK Inhibitors (14):

Cat. No. Product Name Effect Purity
  • HY-15513
    TC-DAPK 6
    		Inhibitor 98.26%
    TC-DAPK 6 is a potent, ATP-competitive, and highly selective DAPK inhibitor (IC50=69 and 225 nM against DAPK1 and DAPK3, respectively, with 10 μM ATP).
  • HY-15847
    HS38
    		Inhibitor ≥99.0%
    HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3), with Kds of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC50 of 200 nM. HS38 can be used for the research of smooth muscle related disorders.
  • HY-122629
    DRAK2-IN-1
    		Inhibitor 99.93%
    DRAK2-IN-1, compound 16, is a potent, selective and ATP-competitive DRAK2 inhibitor with IC50and Kivalues of 3 nM and 0.26 nM, respectively. DRAK2-IN-1 also has inbitory effect on DRAK1 (IC50=51 nM).
  • HY-102069
    3MB-PP1
    		Inhibitor 98.53%
    3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division.
  • HY-145293
    TNIK-IN-3
    		Inhibitor 99.88%
    TNIK-IN-3 is a potent, selective and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK), with an IC50 of 0.026 μM. TNIK-IN-3 could also inhibit Flt4 (IC50=0.030 μM), Flt1 (IC50=0.191 μM) and DRAK1 (IC50=0.411 μM). TNIK-IN-3 can be used for the research of colorectal cancer.
  • HY-117364
    HS148
    		Inhibitor
    HS148 (compound 22) is a selective DAPK3 inhibitor with an Ki value of 119 nM.
  • HY-163626
    STK17A/B-IN-1
    		Inhibitor
    STK17A/B-IN-1 (compound 9) is an orally active, potent, and selective STK17A/B inhibitor with an IC50 of 23 nM against STK17A. STK17A/B-IN-1 can be used for study of cancer.
  • HY-169109
    DAPK1-IN-1
    		Inhibitor
    DAPK1-IN-1 (compound 10) is a death-associated protein kinase 1 (DAPK1) inhibitor with a Kd value of 0.63 μM. DAPK1-IN-1 can be used in Alzheimer’s disease research.
  • HY-149006
    CK156
    		Inhibitor 99.91%
    CK156 is a highly selective death-associated protein kinase (DAPK) inhibitor with IC50s of 182 nM,34 μM, and 39 μM in the DRAK1 NanoBRET assay for DRAK1, CK2a1, and CK2a2, respectively. CK156 can be used for the research of autoimmune and inflammatory diseases.
  • HY-153595
    DAPK-IN-2
    		Inhibitor 98.02%
    DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases.
  • HY-123983
    HS56
    		Inhibitor
    HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with Ki values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension.
  • HY-152954
    DRAK1/2-IN-1
    		Inhibitor
    DRAK1/2-IN-1 (compound 10e) is an active dual DRAK1 and DRAK2 inhibitor with Kd values of 1 μM and 6 μM, respectively.
  • HY-163626A
    STK17A/B-IN-1 hydrochloride
    		Inhibitor
    STK17A/B-IN-1 hydrochloride is an orally active, potent and selective STK17A/B inhibitor with an IC50 value of 23 nM for STK17A. STK17A/B-IN-1 hydrochloride can be used in tumor research.
  • HY-120040
    HS94
    		Inhibitor
    HS94 is a selective DAPK3 inhibitor. HS94 can be used for research of hypertension.